• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过系统实施基于指南的建议降低非肌层浸润性膀胱癌的复发率:对原发性膀胱癌患者进行前瞻性干预的效果

Reducing recurrence in non-muscle-invasive bladder cancer by systematically implementing guideline-based recommendations: effect of a prospective intervention in primary bladder cancer patients.

作者信息

Sörenby Anne, Baseckas Gediminas, Bendahl Pär-Ola, Brändstedt Johan, Håkansson Ulf, Nilsson Stefan, Patschan Oliver, Tinzl Martina, Wokander Mats, Liedberg Fredrik, Gudjonsson Sigurdur

机构信息

a Department of Urology , Skåne University Hospital , Malmö , Sweden.

b Department of Translational Medicine , Lund University , Malmö , Sweden.

出版信息

Scand J Urol. 2019 Apr-Jun;53(2-3):109-115. doi: 10.1080/21681805.2019.1604568. Epub 2019 May 8.

DOI:10.1080/21681805.2019.1604568
PMID:31064253
Abstract

In non-muscle-invasive bladder cancer (NMIBC), local recurrence after transurethral resection of the bladder (TURB) is common. Outcomes vary between urological centres, partly due to the sub-optimal surgical technique and insufficient application of measures recommended in the guidelines. This study evaluated early recurrence rates after primary TURB for NMIBC before and after introducing a standardized treatment protocol. Medical records of all patients undergoing primary TURB for NMIBC in 2010 at Skåne University Hospital, Malmö, Sweden, were reviewed. A new treatment protocol for NMIBC was defined and introduced in 2013, and results documented during the first year thereafter were compared with those recorded in 2010 prior to the intervention. The primary endpoint was early recurrence at first control cystoscopy. Comparisons were made by Chi-square analysis and Fisher's exact test. Recurrence-free survival (RFS) in the two cohorts was also investigated. TURB was performed on 116 and 159 patients before and after the intervention, respectively. The early recurrence rate decreased from 22% to 9.6% ( = 0.005) at the first control cystoscopy after treatment. Residual/Recurrent tumour at the first control cystoscopy after the primary TURB (i.e. at second-look resection or first control cystoscopy) decreased from 31% to 20% ( = 0.038). The proportion of specimens containing muscle in T1 tumours increased from 55% to 94% ( < 0.001). RFS was improved in the intervention group (HR = 0.65, CI = 0.43-1.0;  = 0.05). Introduction of a standardized protocol and reducing the number of surgeons for primary treatment of NMIBC decreased the early recurrence rate from 22% to 9.6% and lowered the recurrence incidence by 35%.

摘要

在非肌层浸润性膀胱癌(NMIBC)中,经尿道膀胱肿瘤切除术(TURB)后局部复发很常见。不同泌尿外科中心的治疗结果存在差异,部分原因是手术技术欠佳以及未充分应用指南中推荐的措施。本研究评估了引入标准化治疗方案前后,NMIBC患者初次TURB后的早期复发率。回顾了2010年在瑞典马尔默斯科讷大学医院接受初次TURB治疗的所有NMIBC患者的病历。2013年定义并引入了一种新的NMIBC治疗方案,并将此后第一年记录的结果与干预前2010年记录的结果进行比较。主要终点是首次膀胱镜检查时的早期复发。采用卡方分析和Fisher精确检验进行比较。还研究了两个队列的无复发生存期(RFS)。干预前后分别有116例和159例患者接受了TURB。治疗后首次膀胱镜检查时的早期复发率从22%降至9.6%(P = 0.005)。初次TURB后首次膀胱镜检查时(即二次探查切除或首次膀胱镜检查时)残余/复发肿瘤从31%降至20%(P = 0.038)。T1期肿瘤标本中含有肌肉的比例从55%增至94%(P < 0.001)。干预组的RFS有所改善(HR = 0.65,CI = 0.43 - 1.0;P = 0.05)。引入标准化方案并减少NMIBC初次治疗的外科医生数量,使早期复发率从22%降至9.6%,复发发生率降低了35%。

相似文献

1
Reducing recurrence in non-muscle-invasive bladder cancer by systematically implementing guideline-based recommendations: effect of a prospective intervention in primary bladder cancer patients.通过系统实施基于指南的建议降低非肌层浸润性膀胱癌的复发率:对原发性膀胱癌患者进行前瞻性干预的效果
Scand J Urol. 2019 Apr-Jun;53(2-3):109-115. doi: 10.1080/21681805.2019.1604568. Epub 2019 May 8.
2
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.EAU 指南:非肌层浸润性膀胱尿路上皮癌:2016 年更新版。
Eur Urol. 2017 Mar;71(3):447-461. doi: 10.1016/j.eururo.2016.05.041. Epub 2016 Jun 17.
3
Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.再次经尿道膀胱肿瘤切除术(re-cTURBT)作为pT1期高级别(HG)疾病复发和进展的风险指标是否有用?一项单中心经验。
Arch Ital Urol Androl. 2017 Dec 31;89(4):272-276. doi: 10.4081/aiua.2017.4.272.
4
Management of high-risk non-muscle invasive bladder cancer.高危非肌层浸润性膀胱癌的管理
Minerva Urol Nefrol. 2012 Dec;64(4):255-60.
5
Impact of substratification on predicting oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor.分层对经尿道膀胱肿瘤切除术治疗的原发性高危非肌肉浸润性膀胱癌患者肿瘤学结局预测的影响。
Urol Oncol. 2020 Oct;38(10):795.e9-795.e17. doi: 10.1016/j.urolonc.2020.04.023. Epub 2020 May 14.
6
The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.膀胱T1期肿瘤患者接受膀胱内丝裂霉素治疗后重复经尿道切除术对复发率和进展率的影响:一项前瞻性随机临床试验。
J Urol. 2006 May;175(5):1641-4. doi: 10.1016/S0022-5347(05)01002-5.
7
Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.对于新诊断的非肌层浸润性膀胱癌,单次广泛经尿道切除术后联合适当的膀胱内灌注治疗的肿瘤学结局。
Int Urol Nephrol. 2015 Sep;47(9):1509-14. doi: 10.1007/s11255-015-1048-3. Epub 2015 Jul 7.
8
Results of a prospective randomized study assessing the efficacy of fluorescent cystoscopy-assisted transurethral resection and single instillation of doxorubicin in patients with non-muscle-invasive bladder cancer.一项前瞻性随机研究的结果,该研究评估了荧光膀胱镜辅助经尿道切除术及阿霉素单次灌注对非肌层浸润性膀胱癌患者的疗效。
World J Urol. 2017 May;35(5):745-752. doi: 10.1007/s00345-016-1927-y. Epub 2016 Sep 7.
9
The impact of frequent cystoscopy on surgical care and cancer outcomes among patients with low-risk, non-muscle-invasive bladder cancer.在低危、非肌肉浸润性膀胱癌患者中,频繁膀胱镜检查对手术护理和癌症结果的影响。
Cancer. 2019 Sep 15;125(18):3147-3154. doi: 10.1002/cncr.32185. Epub 2019 May 23.
10
Hexaminolevulinate blue light cystoscopy (Hal) assisted transurethral resection of the bladder tumour vs white light transurethral resection of the bladder tumour in non-muscle invasive bladder cancer (NMIBC) : a retrospective analysis.六亚甲基蓝光膀胱镜检查(Hal)辅助经尿道膀胱肿瘤切除术与非肌肉浸润性膀胱癌(NMIBC)的白光经尿道膀胱肿瘤切除术:回顾性分析。
Arch Ital Urol Androl. 2020 Apr 6;92(1):17-20. doi: 10.4081/aiua.2020.1.17.

引用本文的文献

1
Recent Advances and Emerging Innovations in Transurethral Resection of Bladder Tumor (TURBT) for Non-Muscle Invasive Bladder Cancer: A Comprehensive Review of Current Literature.非肌层浸润性膀胱癌经尿道膀胱肿瘤切除术(TURBT)的最新进展与新兴创新:当前文献综述
Res Rep Urol. 2025 Mar 14;17:69-85. doi: 10.2147/RRU.S386026. eCollection 2025.
2
Does Blue Light Cystoscopy Reduce Recurrences of Non-Muscle Invasive Bladder Cancer?蓝光膀胱镜检查能否降低非肌层浸润性膀胱癌的复发率?
Bladder Cancer. 2023 Mar 31;9(1):105-107. doi: 10.3233/BLC-239001. eCollection 2023.
3
Reply to Fredrik Liedberg and Johannes Bobjer's Letter to the Editor re: Rakesh Heer, Rebecca Lewis, Thenmalar Vadiveloo, et al. A Randomized Trial of PHOTOdynamic Surgery in Non-muscle-invasive Bladder Cancer. NEJM Evid. In press. https://doi.org/10.1056/EVIDoa2200092.
回复弗雷德里克·利德伯格和约翰内斯·博耶尔致编辑的信,主题为:拉凯什·希尔、丽贝卡·刘易斯、坦马拉·瓦迪韦卢等人。非肌层浸润性膀胱癌光动力手术的随机试验。《新英格兰医学杂志·循证医学》。即将发表。https://doi.org/10.1056/EVIDoa2200092 。
Eur Urol Open Sci. 2022 Nov 17;46:149-150. doi: 10.1016/j.euros.2022.10.019. eCollection 2022 Dec.
4
Re: Rakesh Heer, Rebecca Lewis, Thenmalar Vadiveloo, et al. A Randomized Trial of PHOTOdynamic Surgery in Non-muscle-invasive Bladder Cancer. NEJM Evid. In press. https://doi.org/10.1056/EVIDoa2200092.回复:拉凯什·希尔、丽贝卡·刘易斯、坦马拉·瓦迪韦卢等。非肌层浸润性膀胱癌光动力手术的随机试验。《新英格兰医学杂志·证据》。即将发表。https://doi.org/10.1056/EVIDoa2200092 。
Eur Urol Open Sci. 2022 Oct 26;46:53-54. doi: 10.1016/j.euros.2022.09.021. eCollection 2022 Dec.
5
Clinical determinants of recurrence in pTa bladder cancer following transurethral resection of bladder tumor.经尿道膀胱肿瘤切除术治疗后 pTa 膀胱癌复发的临床决定因素。
BMC Cancer. 2022 Jun 8;22(1):631. doi: 10.1186/s12885-022-09733-8.
6
SULF2 is a novel diagnostic and prognostic marker for high-grade bladder cancer with lymphatic metastasis.SULF2是一种用于伴有淋巴转移的高级别膀胱癌的新型诊断和预后标志物。
Ann Transl Med. 2021 Sep;9(18):1439. doi: 10.21037/atm-21-4102.